JNJ

192.81

+0.35%↑

ABT

127.86

+0.06%↑

MDT

95.84

-0.02%↓

VEEV

289.4

-0.16%↓

A

145.98

+0.05%↑

JNJ

192.81

+0.35%↑

ABT

127.86

+0.06%↑

MDT

95.84

-0.02%↓

VEEV

289.4

-0.16%↓

A

145.98

+0.05%↑

JNJ

192.81

+0.35%↑

ABT

127.86

+0.06%↑

MDT

95.84

-0.02%↓

VEEV

289.4

-0.16%↓

A

145.98

+0.05%↑

JNJ

192.81

+0.35%↑

ABT

127.86

+0.06%↑

MDT

95.84

-0.02%↓

VEEV

289.4

-0.16%↓

A

145.98

+0.05%↑

JNJ

192.81

+0.35%↑

ABT

127.86

+0.06%↑

MDT

95.84

-0.02%↓

VEEV

289.4

-0.16%↓

A

145.98

+0.05%↑

Search

Innoviva Inc

Cerrado

SectorSalud

18.35 5.46

Resumen

Variación precio

24h

Actual

Mínimo

17.15

Máximo

18.77

Métricas clave

By Trading Economics

Ingresos

110M

64M

Ventas

12M

100M

P/B

Media del Sector

30.193

37.461

Margen de beneficio

63.508

Empleados

127

EBITDA

111M

84M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+118.39% upside

Dividendos

By Dow Jones

Próximas Ganancias

4 nov 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-82M

1.1B

Apertura anterior

12.89

Cierre anterior

18.35

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

168 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bullish Evidence

Innoviva Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

22 oct 2025, 22:47 UTC

Adquisiciones, fusiones, absorciones

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project -- Update

22 oct 2025, 22:13 UTC

Adquisiciones, fusiones, absorciones

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project

22 oct 2025, 21:20 UTC

Ganancias

Correction to IBM 3Q Sales Jump Article

22 oct 2025, 20:57 UTC

Ganancias

SAP Posts Higher 3Q Revenue, Operating Profit

22 oct 2025, 23:46 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

22 oct 2025, 23:46 UTC

Charlas de Mercado

Nikkei May Decline Amid U.S.-China Trade Tensions -- Market Talk

22 oct 2025, 23:41 UTC

Charlas de Mercado

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

22 oct 2025, 23:38 UTC

Charlas de Mercado

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

22 oct 2025, 23:15 UTC

Ganancias

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 4th Update

22 oct 2025, 22:28 UTC

Charlas de Mercado

Alcoa Cautions About Spending More on U.S. Smelters -- Market Talk

22 oct 2025, 22:02 UTC

Ganancias

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 3rd Update

22 oct 2025, 21:59 UTC

Adquisiciones, fusiones, absorciones

Williams Cos.: Entered Into 1.5 Mtpa LNG Offtake Obligation >WMB

22 oct 2025, 21:58 UTC

Adquisiciones, fusiones, absorciones

Williams Cos. to Buy 10% Interest in Louisiana LNG LLC >WMB

22 oct 2025, 21:57 UTC

Adquisiciones, fusiones, absorciones

Williams Cos. to Buy 80% Ownership In, Become Operator of Driftwood Pipeline >WMB

22 oct 2025, 21:56 UTC

Adquisiciones, fusiones, absorciones

Williams Cos.: Strategic Partnership Entered With Woodside Energy to Invest in Louisiana LNG Project >WMB

22 oct 2025, 21:47 UTC

Adquisiciones, fusiones, absorciones

Woodside: Williams to Assume LNG Offtake Obligations for 10% of Produced Volumes

22 oct 2025, 21:47 UTC

Ganancias

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

22 oct 2025, 21:47 UTC

Adquisiciones, fusiones, absorciones

Woodside: Williams to Contribute Its Share of Capex for LNG Facility, Pipeline

22 oct 2025, 21:46 UTC

Adquisiciones, fusiones, absorciones

Woodside Energy Says Williams Deals Worth US$378 Million Including Capital Reimbursement

22 oct 2025, 21:45 UTC

Adquisiciones, fusiones, absorciones

Woodside Energy to Sell 80% Interest in Driftwood Pipeline Co. to Williams

22 oct 2025, 21:45 UTC

Adquisiciones, fusiones, absorciones

Woodside Energy to Sell 10% Interest in Louisiana LNG Holding Co. to Williams

22 oct 2025, 21:28 UTC

Charlas de Mercado
Ganancias

Correction to Alcoa Tariff Market Talk

22 oct 2025, 21:25 UTC

Ganancias

Wall Street Wonders if Grail's Cancer Test Results Are a True Positive -- Barrons.com

22 oct 2025, 21:17 UTC

Ganancias

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 2nd Update

22 oct 2025, 21:09 UTC

Charlas de Mercado
Ganancias

Alcoa Says Delivery Fee Covering Tariff Costs -- Market Talk

22 oct 2025, 21:00 UTC

Charlas de Mercado

ESG Roundup: Market Talk

22 oct 2025, 20:59 UTC

Ganancias

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

22 oct 2025, 20:51 UTC

Ganancias

SAP Reports Mixed Earnings. The Stock is Down. -- Barrons.com

22 oct 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

22 oct 2025, 20:44 UTC

Ganancias

Kaiser Aluminum: For the Full Yr 2025, Now Expects Conversion Rev to Be Flat to Up 5% Yr-Over-Yr and Raises Adjusted EBITDA Outlook to Improve 20% to 25% Yr-Over-Yr >KALU

Comparación entre iguales

Cambio de precio

Innoviva Inc Esperado

Precio Objetivo

By TipRanks

118.39% repunte

Estimación a 12 meses

Media 38 USD  118.39%

Máximo 55 USD

Mínimo 17 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Innoviva Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

4 ratings

3

Comprar

0

Mantener

1

Vender

Puntuación técnica

By Trading Central

18.57 / 18.75Soporte y Resistencia

Corto Plazo

Strong Bullish Evidence

Medio plazo

Weak Bullish Evidence

Largo Plazo

Neutral Evidence

Sentimiento

By Acuity

168 / 371 Clasificación en Salud

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
help-icon Live chat